The Effect of Endothelin Receptor Antagonists in Patients with Eisenmenger Syndrome: A Systematic Review

  • Abdelrahman Elshafay, Duy Hieu Truong, Mohamed M. AboElnas, Hossam Idrees, Hatem G. Metwali, Nguyen Lam Vuong, Omar Ahmed Saad, Kenji Hirayama, Nguyen Tien Huy
  • American Journal of Cardiovascular Drugs, June 2017, Springer Science + Business Media
  • DOI: 10.1007/s40256-017-0240-5

What is it about?

The efficacy of endothelin receptor antagonists (ERAs) in the management of Eisenmenger syndrome (ES) remains controversial. The aim of this study is to systemically review the safety and effects of ERAs in improving the quality of life and basic cardiac functions of these patients.

Why is it important?

This study demonstrated safety and improved hemodynamic effects of bosentan in ES, with a controversial effect on exercise capacity. Further randomized controlled trials with longer follow-up duration are needed to confirm these results.

Read Publication

http://dx.doi.org/10.1007/s40256-017-0240-5

The following have contributed to this page: Mr Duy Hieu Truong